Drug Trial Radar · NCT07460518
Tranexamic Acid for Bleeding Reduction During TURP Surgery
Last checked: Nov 20, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Mar 30, 2026
Primary completion
Oct 30, 2026
Study completion Oct 30, 2026
Sponsor
- Lead sponsor
- Hamza NajoutAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Transurethral resection of the prostate (TURP) is commonly performed in elderly patients and may be associated with perioperative bleeding leading to postoperative anemia and delayed recovery. Tranexamic acid (TXA), an antifibrinolytic agent, may reduce surgical bleeding by inhibiting fibrin degradation. This prospective randomized quadruple-blind placebo-controlled clinical trial evaluates whether perioperative administration of intravenous tranexamic acid reduces intraoperative blood loss and preserves postoperative hemoglobin concentration in patients undergoing TURP under standardized spinal anesthesia. Participants are randomly assigned to receive either intravenous tranexamic acid or placebo prior to surgery. The primary outcomes assess objective measures of perioperative blood loss and postoperative hemoglobin levels. Secondary outcomes include recovery parameters, perioperative safety, and exploratory hospital-level economic impact. The study aims to determine whether anesthesia-led haemostatic optimization using tranexamic acid improves perioperative physiological stability and recovery efficiency within an enhanced recovery framework.
Conditions
- Benign Prostatic Hyperplasia
- Transurethral Resection of the Prostate
- Perioperative Bleeding
- Anemia, Postoperative
Interventions
Tranexamic AcidDrug
Intravenous tranexamic acid administered at a dose of 10 mg/kg approximately 30 minutes before surgical resection to reduce perioperative bleeding during transurethral resection of the prostate.
Placebo (Normal Saline)Drug
Intravenous administration of normal saline placebo prepared to be identical in appearance and volume to the tranexamic acid solution to maintain blinding.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total Hemoglobin Mass Recovered in Irrigation EffluentTime frame: During surgery (from start of resection to end of procedure, up to 3 hours)
- Postoperative Hemoglobin ConcentrationTime frame: 24 hours after surgery
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mohammed V Military Teaching Hospital
Rabat, Morocco · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.